E-LIB Suche - Ergebnisse für: Liang, Chris

1

Efficacy and Safety of TLL-018 in Moderate to Severe Chroni..:

Lu, Qianjin ; Yang, Bin ; Liu, Lunfei...
Journal of Allergy and Clinical Immunology. 153 (2024) 2 - p. AB372 , 2024

Link: https://doi.org/10.1016/..

2

Safety and tolerability of oral vorolanib for neovascular (..:

Gao, Yunxia ; Lu, Fang ; Li, Xiaoxin...
Eye. 37 (2023) 15 - p. 3228-3233 , 2023

Link: https://doi.org/10.1038/..

3

Race and Gender Representation in College and Career Readin..:

Freeman, Jennifer ; Carter, Devon ; Kern, Lee...
Career Development and Transition for Exceptional Individuals. , 2023

Link: https://doi.org/10.1177/..

4

Prioritizing ecological restoration of converted lands in C..:

Currie, Jessica ; Merritt, Will ; Liang, Chris...
Conservation Science and Practice. 5 (2023) 6 - p. , 2023

Link: https://doi.org/10.1111/..

5

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with i..:

Bagegni, Nusayba A. ; Park, Haeseong ; Kraft, Katlyn...
Cancer Chemotherapy and Pharmacology. 89 (2022) 4 - p. 487-497 , 2022

Link: https://doi.org/10.1007/..

6

Vorolanib, a novel tyrosine receptor kinase receptor inhibi..:

Liang, Chris ; Yuan, Xiaobin ; Shen, Zhilin..
Molecular Therapy - Oncolytics. 24 (2022) - p. 577-584 , 2022

Link: https://doi.org/10.1016/..

7

Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine k..:

Pedersen, Katrina S. ; Grierson, Patrick M. ; Picus, Joel...
Investigational New Drugs. 39 (2021) 5 - p. 1298-1305 , 2021

Link: https://doi.org/10.1007/..

8

Preservers of XR Technologies and Transhumanism as Dynamica..:

, In: Advances in Intelligent Systems and Computing; Proceedings of the Future Technologies Conference (FTC) 2020, Volume 2,

Semwal, Sudhanshu Kumar ; Jackson, Ron ; Liang, Chris.. - p. 300-309 , 2020

Link: https://doi.org/10.1007/..

9

Assessing the vulnerability of Africa's freshwater fishes t..:

Nyboer, Elizabeth A. ; Liang, Chris ; Chapman, Lauren J.
Biological Conservation. 236 (2019) - p. 505-520 , 2019

Link: https://doi.org/10.1016/..

10

Dual PI3 K/mTOR inhibition reduces prostate cancer bone eng..:

Mancini, Andrea ; Colapietro, Alessandro ; Pompili, Simona...
Tumor Biology. 40 (2018) 4 - p. 101042831877177 , 2018

Link: https://doi.org/10.1177/..

11

Phase I, First-in-Human, Dose-Escalation Study to Evaluate ..:

Bendell, Johanna C. ; Patel, Manish R. ; Moore, Kathleen N....
The Oncologist. 24 (2018) 4 - p. 455-e121 , 2018

Link: https://doi.org/10.1634/..

12

Pharmacodynamic study using FLT PET/CT in advanced solid ma..:

Scarpelli, Matthew ; Rampurwala, Murtuza ; Eickhoff, Jens...
Cancer Chemotherapy and Pharmacology. 82 (2018) 2 - p. 211-219 , 2018

Link: https://doi.org/10.1007/..

13

P3.02a-001 Response and Plasma Genotyping from Phase I/II T..:

Horn, Leora ; Wakelee, Heather ; Reckamp, Karen...
Journal of Thoracic Oncology. 12 (2017) 1 - p. S1159 , 2017

Link: https://doi.org/10.1016/..

14

New therapeutic strategies in neuroblastoma: combined targe..:

Di Paolo, Daniela ; Yang, D. ; Pastorino, Fabio...
Oncotarget. 6 (2015) 30 - p. 28774-28789 , 2015

Link: https://doi.org/10.18632..

15

Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/..:

Wang, Xiang ; Zhang, Xi ; Li, Ben-shang...
Oncotarget. 5 (2014) 21 - p. 10732-10744 , 2014

Link: https://doi.org/10.18632..